Prof. Dr. med. Dirk Schadendorf
6 clinical trials · Sponsor
◉ Watch Prof. Dr. med. Dirk Schadendorf
| Record | Firm | Date |
|---|---|---|
| Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma (NCT02902042) | Prof. Dr. med. Dirk Schadendorf | 2018-04-24 |
Track Prof. Dr. med. Dirk Schadendorf automatically
Every clearance here is in the API, with alerts when new ones post.